Recurring-Revenue Business Based on Consumables and Maintenance for Automated Cell Culture Equipment
First written in FY2024-Q1. 4 of 5 entries say "Restated". Latest entry: 2026-05-14.
37 other companies' latest entry also says "Restated".
- 2026-05-14RestatedEarnings
「Maintenance services for previously delivered automated cell culture equipment and sales of consumables progressed favorably, resulting in sales performance broadly in line with the plan.」
The company reconfirmed recurring revenue from maintenance services and consumables sales for previously delivered automated cell culture equipment. - FY2025-H1RestatedAnnual report
「In the life sciences area, sales of the automated cell culture system “MakCell®,” together with equipment maintenance and consumables sales, enabled the company to maintain revenue at the same level as the previous year.」
In addition to sales of automated cell culture systems, the company maintained recurring revenue from equipment maintenance and consumables sales. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, performance in the life sciences area was supported by equipment maintenance, consumables sales and made-to-order systems, while the equipment development area benefited from projects involving improvements to made-to-order systems and test processing using next-generation processing and polishing systems.」
In addition to recurring revenue from equipment maintenance and consumables sales, made-to-order systems and test processing projects contributed to performance. - FY2024-Q2RestatedAnnual report
「In the life sciences and equipment development business, revenue for the cumulative second quarter of the current consolidated fiscal year was supported by equipment maintenance, consumables sales and made-to-order systems for major pharmaceutical companies in the life sciences area, and by projects involving electronic transport components for synchrotron radiation facilities in the equipment development area.」
In addition to recurring revenue from equipment maintenance and consumables sales, made-to-order systems for major pharmaceutical companies contributed to revenue. - FY2024-Q1First statedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, sales were centered on recurring businesses, including consumables related to automated cell culture systems and system maintenance and inspection fees.」
For the first time, the company disclosed as an independent theme that sales of consumables related to automated cell culture systems and system maintenance and inspection fees formed the core of its sales performance as recurring businesses.